| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PSCA |
| Uniprot No | O43653 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-95aa |
| 氨基酸序列 | CYSCKAQVSNEDCLQVENCTQLGEQCWTARIRAVGLLTVISKGCSLNCVD DSQDYYVGKKNITCCDTDLCNAS |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PSCA(前列腺干细胞抗原)重组蛋白的参考文献示例(内容基于假设性研究，供参考)：
---
1. **文献名称**：*Production and characterization of recombinant PSCA for immunotherapy of prostate cancer*
**作者**：Smith J, et al.
**摘要**：研究报道了在大肠杆菌系统中高效表达并纯化重组PSCA蛋白，通过体外实验验证其与特异性抗体的结合能力，并证明其在小鼠模型中可诱导抗肿瘤T细胞反应，为前列腺癌疫苗开发奠定基础。
2. **文献名称**：*Recombinant PSCA-based ELISA for early detection of prostate cancer*
**作者**：Lee H, et al.
**摘要**：利用哺乳动物细胞表达系统(如CHO细胞)制备高纯度重组PSCA蛋白，开发新型ELISA检测方法，临床样本分析显示其在区分前列腺癌患者与健康人群中的敏感性和特异性优于传统标志物PSA。
3. **文献名称**：*Structural insights into PSCA by recombinant protein crystallization*
**作者**：Brown R, et al.
**摘要**：通过昆虫细胞表达系统获得重组PSCA胞外结构域，利用X射线晶体学解析其三维结构，揭示了关键抗原表位，为基于结构的靶向药物设计提供了分子基础。
---
**注**：以上文献为示例，实际引用时需查询具体数据库(如PubMed、Web of Science)获取真实发表的研究。
Prostate Stem Cell Antigen (PSCA) is a cell surface glycoprotein belonging to the Thy-1/Ly-6 family of glycosylphosphatidylinositol (GPI)-anchored proteins. Initially identified in prostate cancer, PSCA is expressed in normal prostate epithelial cells and exhibits overexpression in multiple malignancies, including prostate, bladder, pancreatic, and gastric cancers. Its role in tumorigenesis involves promoting cell proliferation, survival, and metastasis, making it a promising therapeutic target. PSCA’s restricted expression in normal tissues and upregulated presence in tumors have also positioned it as a potential biomarker for cancer diagnosis and prognosis.
Recombinant PSCA proteins are engineered through genetic modification, typically expressed in bacterial, yeast, or mammalian cell systems. These proteins retain key structural and functional domains, enabling their use in immunological, biochemical, and therapeutic studies. For instance, recombinant PSCA serves as an antigen in antibody development, facilitating the creation of monoclonal antibodies for targeted cancer therapies. It is also employed in vaccine development to stimulate anti-tumor immune responses by presenting PSCA epitopes to immune cells.
Research on PSCA recombinant proteins has advanced preclinical studies, particularly in antibody-drug conjugates (ADCs) and CAR-T cell therapies. Structural studies using recombinant PSCA have elucidated its interaction with antibodies, aiding in the optimization of binding affinity and specificity. Challenges remain, such as minimizing off-target effects and overcoming tumor heterogeneity, but ongoing efforts aim to translate PSCA-targeted strategies into clinical applications. Overall, PSCA recombinant proteins represent a critical tool in both understanding cancer biology and developing precision oncology therapeutics.
×
